CVI
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Author's Correction for Churdboonchart et al., Clin. Diagn. Lab. Immunol. 7 (5) 728-733.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Churdboonchart, V.
Right arrow Articles by Moss, R.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Churdboonchart, V.
Right arrow Articles by Moss, R.

 Previous Article

Clinical and Diagnostic Laboratory Immunology, November 2001, p. 1295-1295, Vol. 8, No. 6
1071-412X/01   DOI:
Copyright © 2001, American Society for Microbiology. All rights reserved.

AUTHOR'S CORRECTION

A Double-Blind, Adjuvant-Controlled Trial of Human Immunodeficiency Virus Type 1 (HIV-1) Immunogen (Remune) Monotherapy in Asymptomatic, HIV-1-Infected Thai Subjects with CD4-Cell Counts of >300

V. Churdboonchart, C. Sakondhavat, S. Kulpradist, B. Isarangkura Na Ayudthya, V. Chandeying, S. Rugpao, C. Boonshuyar, W. Sukeepaisarncharoen, W. Sirawaraporn, D. J. Carlo, and R. Moss

Faculty of Science and Department of Biostatistics, Faculty of Public Health, Mahidol University, Vajira Hospital, Bangkok, Metropolitan Authority, and Pramongkutklao College of Medicine, Bangkok, Khon Kaen University Hospital, Khon Kaen, Songklanakarindh University, Songkla, and Chiang Mai University, Chiang Mai, Thailand, and The Immune Response Corporation, Carlsbad, California

Volume 7, no. 5, p. 728-733, 2000. The commercial affiliation, equity interests, and patent-licensing arrangement of Dr. Churdboonchart were not disclosed in the manuscript submittal letter. Dr. Churdboonchart was associated with the Trinity Medical Group Co., Ltd., which was formed to sponsor the clinical trial of Remune in Thailand through a collaborative and license agreement with the Immune Response Corporation, the maker of Remune.

Clinical and Diagnostic Laboratory Immunology, November 2001, p. 1295-1295, Vol. 8, No. 6
1071-412X/01   DOI:
Copyright © 2001, American Society for Microbiology. All rights reserved.



This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Churdboonchart, V.
Right arrow Articles by Moss, R.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Churdboonchart, V.
Right arrow Articles by Moss, R.

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev. Infect. Immun.
J. Clin. Microbiol. J. Virol. ALL ASM JOURNALS